Delaney Brendan 4
4 · IMMUNOMEDICS INC · Filed Mar 18, 2019
Insider Transaction Report
Form 4
IMMUNOMEDICS INCIMMU
Delaney Brendan
Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2019-03-14+51,320→ 51,320 totalExercise: $17.94Exp: 2026-03-14→ Common Stock, par value $0.01 per share (51,320 underlying) - Award
Stock Option (right to buy)
2019-03-14+25,660→ 25,660 totalExercise: $17.94Exp: 2026-03-14→ Common Stock, par value $0.01 per share (25,660 underlying)
Footnotes (2)
- [F1]The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter.
- [F2]The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant.